<DOC>
	<DOCNO>NCT00070278</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , epirubicin , cyclophosphamide , paclitaxel , gemcitabine use different way stop tumor cell divide stop grow die . Giving combination chemotherapy surgery may shrink tumor remove surgery . It yet know combination chemotherapy regimen effective treat early breast cancer . PURPOSE : This randomized phase III trial study different regimen combination chemotherapy compare well work treat woman undergo surgery early invasive breast cancer .</brief_summary>
	<brief_title>Neoadjuvant Epirubicin , Cyclophosphamide , Paclitaxel With Without Gemcitabine Treating Women Who Are Undergoing Surgery Early Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare complete pathological response rate woman poor-risk early breast cancer treat neoadjuvant sequential epirubicin , cyclophosphamide , paclitaxel v without gemcitabine . Secondary - Compare disease-free overall survival patient treat regimen . - Compare toxicity regimens patient . - Compare effect regimens prognostic factor patient . - Correlate molecular profile , specific gene mutation , genomic gene expression change clinical outcome patient . - Compare quality life patient treat regimen . - Determine health economics associate study . OUTLINE : This randomize , multicenter study . Patients stratify accord estrogen-receptor status ( negative v great 10 % positive cell ) , HER-2 status ( positive v negative ) , tumor size ( 30-50 mm v great 50 mm ) , clinical involvement axillary node ( yes v ) . Patients randomize 1 4 treatment arm . - Neoadjuvant sequential chemotherapy : - Arm I : Patients receive epirubicin IV cyclophosphamide IV day 1 . Treatment repeat every 21 day 4 course . Patients receive paclitaxel IV 3 hour day 1 . Treatment repeat every 21 day 4 course . - Arm II : Patients receive paclitaxel arm I follow epirubicin cyclophosphamide arm I . - Arm III : Patients receive epirubicin cyclophosphamide arm I follow paclitaxel arm I gemcitabine IV 30 minute day 1 8 . Treatment repeat every 21 day 4 course . - Arm IV : Patients receive paclitaxel arm I gemcitabine arm III follow epirubicin cyclophosphamide arm I . - Surgery : After completion neoadjuvant chemotherapy , patient arm undergo definitive surgery . Tumor tissue remove subset patient serial biopsy . Molecular genetic profiling , mutation analysis , comparative genomic analysis perform tissue sample . Quality life assess baseline , 4 course chemotherapy , completion chemotherapy , surgery , every 6 month 2 year . Patients follow every 2 month 2 year every 3 month 3 year . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 800 patient ( 200 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive breast cancer Grade 2 3 Tumor size least 3 cm ultrasound No evidence metastatic disease Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age Not specify Sex Female Menopausal status Not specify Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Fit receive study chemotherapy PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>